Trial intelligence / Profile preview

Phase II open-label study of dacomitinib for EGFR-mutated NSCLC with brain metastases

ChiCTR2000036939Phase 4Recruiting

Sponsor

Shanghai Chest Hospital

Start

Aug 2020

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1